NASDAQ:NEO - NeoGenomics Stock Price, Forecast & News

NeoGenomics' stock was trading at $24.78 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, NEO stock has increased by 3.8% and is now trading at $25.71. View which stocks have been mosted impacted by Coronavirus.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last year. There are currently 6 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for NeoGenomics.

NeoGenomics is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for NeoGenomics.

NeoGenomics, Inc. (NASDAQ:NEO) announced its quarterly earnings results on Thursday, February, 27th. The medical research company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.04. The medical research company earned $106.90 million during the quarter, compared to analyst estimates of $104.25 million. NeoGenomics had a return on equity of 5.27% and a net margin of 1.96%. The firm's quarterly revenue was up 39.4% on a year-over-year basis. During the same quarter last year, the business posted $0.06 EPS. View NeoGenomics' earnings history.

NeoGenomics updated its FY 2020 Pre-Market earnings guidance on Thursday, February, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $464-474 million, compared to the consensus revenue estimate of $448.31 million.

7 brokerages have issued 12 month price objectives for NeoGenomics' stock. Their forecasts range from $30.00 to $38.00. On average, they expect NeoGenomics' share price to reach $33.00 in the next twelve months. This suggests a possible upside of 28.4% from the stock's current price. View analysts' price targets for NeoGenomics.

Press coverage about NEO stock has trended somewhat positive this week, according to InfoTrie. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. NeoGenomics earned a daily sentiment score of 1.2 on InfoTrie's scale. They also gave news articles about the medical research company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news aboutNeoGenomics.

Some companies that are related to NeoGenomics include Insulet (PODD), Steris (STE), West Pharmaceutical Services (WST), Sonic Healthcare (SHL), Straumann (SAUHF), Ramsay Health Care Limited Fully Paid Ord. Shrs (RHC), Bio-Rad Laboratories (BIO), Bio-Rad Laboratories (BIO.B), Varian Medical Systems (VAR), Cochlear (COH), Qiagen (QGEN), Masimo (MASI), Davita (DVA), Eurofins Scientific (ERFSF) and Ono Pharmaceutical (OPHLF).

Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Marvell Technology Group (MRVL), Alibaba Group (BABA), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), AbbVie (ABBV), Netflix (NFLX), Intel (INTC), CVS Health (CVS) and Amarin (AMRN).

NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."

NeoGenomics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Kopp Family Office LLC (4.64%), Janus Henderson Group PLC (3.33%), Artisan Partners Limited Partnership (2.81%), State Street Corp (2.65%), Eagle Asset Management Inc. (2.38%) and Granite Investment Partners LLC (1.84%). Company insiders that own NeoGenomics stock include Electric Co General, George Cardoza, Jennifer Balliet, Kathryn B Mckenzie, Kevin C Johnson, Lynn A Tetrault, Oort Douglas M Van, Raymond R Hipp, Robert J Shovlin, Steven A Ross, Steven C Jones and William Bonello. View institutional ownership trends for NeoGenomics.

NEO stock was sold by a variety of institutional investors in the last quarter, including Emerald Mutual Fund Advisers Trust, Marshall Wace LLP, Emerald Advisers LLC, Franklin Resources Inc., Franklin Resources Inc., Eagle Asset Management Inc., Janus Henderson Group PLC, and Falcon Point Capital LLC. Company insiders that have sold NeoGenomics company stock in the last year include George Cardoza, Jennifer Balliet, Kathryn B Mckenzie, Oort Douglas M Van, Raymond R Hipp, Robert J Shovlin, Steven C Jones, and William Bonello. View insider buying and selling activity for NeoGenomics.

NEO stock was purchased by a variety of institutional investors in the last quarter, including Kopp Family Office LLC, Norges Bank, Artisan Partners Limited Partnership, Redwood Investments LLC, Driehaus Capital Management LLC, Candriam Luxembourg S.C.A., TCW Group Inc., and California Public Employees Retirement System. View insider buying and selling activity for NeoGenomics.

Shares of NEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NEO stock can currently be purchased for approximately $25.71.

NeoGenomics has a market capitalization of $2.70 billion and generates $408.83 million in revenue each year. The medical research company earns $8.01 million in net income (profit) each year or $0.23 on an earnings per share basis. NeoGenomics employs 1,700 workers across the globe. View additional information about NeoGenomics.

The official website for NeoGenomics is http://www.neogenomics.com/.

NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The medical research company can be reached via phone at 239-768-0600 or via email at [email protected]